III期临床研究-话题@MedSci

#III期临床研究#

70篇内容 | 2423人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2050169, encodeId=90e52050169f8, content=<a href='/topic/show?id=581595e015' target=_blank style='color:#2F92EE;'>#III期临床研究#</a>, objectTitle=维昇药业宣布其TransCon人生长激素将在国内开展III期临床研究, objectType=article, longId=182123, objectId=bacc18212334, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bacc18212334, replyNumber=0, likeNumber=70, createdTime=2020-07-27, rootId=0, userName=tastas, userId=47c5349, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bacc18212334, moduleTitle=维昇药业宣布其TransCon人生长激素将在国内开展III期临床研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bacc18212334)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2050164, encodeId=9aff205016414, content=<a href='/topic/show?id=581595e015' target=_blank style='color:#2F92EE;'>#III期临床研究#</a>, objectTitle=Strekin AG获得282万瑞士法郎的A轮融资，以完成STR001治疗突发感觉神经性听力损失的III期临床研究, objectType=article, longId=178786, objectId=cbc51e8786dd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cbc51e8786dd, replyNumber=0, likeNumber=63, createdTime=2020-05-02, rootId=0, userName=tastas, userId=47c5349, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cbc51e8786dd, moduleTitle=Strekin AG获得282万瑞士法郎的A轮融资，以完成STR001治疗突发感觉神经性听力损失的III期临床研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cbc51e8786dd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2050171, encodeId=8b2c20501e1aa, content=<a href='/topic/show?id=581595e015' target=_blank style='color:#2F92EE;'>#III期临床研究#</a>, objectTitle=J Gastroenterology：维多珠单抗对日本克罗恩病患者的疗效影响——III期临床研究 , objectType=article, longId=189573, objectId=89671895e3b8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=89671895e3b8, replyNumber=0, likeNumber=67, createdTime=2020-11-12, rootId=0, userName=tastas, userId=47c5349, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=89671895e3b8, moduleTitle=J Gastroenterology：维多珠单抗对日本克罗恩病患者的疗效影响——III期临床研究 , moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=89671895e3b8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2050165, encodeId=667b20501652d, content=<a href='/topic/show?id=581595e015' target=_blank style='color:#2F92EE;'>#III期临床研究#</a>, objectTitle=秦叔逵教授：呋喹替尼三线治疗中国转移性结直肠癌的III期临床研究（FRESCO）中的肝转移亚组分析|CSCO2019, objectType=article, longId=179755, objectId=246d1e9755d6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=246d1e9755d6, replyNumber=0, likeNumber=57, createdTime=2019-12-17, rootId=0, userName=tastas, userId=47c5349, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=246d1e9755d6, moduleTitle=秦叔逵教授：呋喹替尼三线治疗中国转移性结直肠癌的III期临床研究（FRESCO）中的肝转移亚组分析|CSCO2019, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=246d1e9755d6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2050162, encodeId=d46b205016242, content=<a href='/topic/show?id=581595e015' target=_blank style='color:#2F92EE;'>#III期临床研究#</a>, objectTitle=全球III期临床研究：roxadustat的心血管安全性得到证实, objectType=article, longId=165928, objectId=8d7416592893, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8d7416592893, replyNumber=0, likeNumber=55, createdTime=2020-01-21, rootId=0, userName=tastas, userId=47c5349, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8d7416592893, moduleTitle=全球III期临床研究：roxadustat的心血管安全性得到证实, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8d7416592893)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2050167, encodeId=89d2205016eb2, content=<a href='/topic/show?id=581595e015' target=_blank style='color:#2F92EE;'>#III期临床研究#</a>, objectTitle=III期临床研究CheckMate -9LA达到主要研究终点，与单独化疗相比，欧狄沃®（纳武利尤单抗）与低剂量伊匹木单抗联合化疗用于肺癌一线治疗，患者总生存获益, objectType=article, longId=181894, objectId=a3881818949e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a3881818949e, replyNumber=0, likeNumber=106, createdTime=2020-04-30, rootId=0, userName=tastas, userId=47c5349, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a3881818949e, moduleTitle=III期临床研究CheckMate -9LA达到主要研究终点，与单独化疗相比，欧狄沃®（纳武利尤单抗）与低剂量伊匹木单抗联合化疗用于肺癌一线治疗，患者总生存获益, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a3881818949e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2050163, encodeId=c412205016372, content=<a href='/topic/show?id=581595e015' target=_blank style='color:#2F92EE;'>#III期临床研究#</a>, objectTitle=罗沙司他全球III期临床研究证实其心血管安全性, objectType=article, longId=166305, objectId=121416630562, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=121416630562, replyNumber=0, likeNumber=84, createdTime=2019-11-22, rootId=0, userName=tastas, userId=47c5349, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=121416630562, moduleTitle=罗沙司他全球III期临床研究证实其心血管安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=121416630562)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2050170, encodeId=1fdd20501e0ad, content=<a href='/topic/show?id=581595e015' target=_blank style='color:#2F92EE;'>#III期临床研究#</a>, objectTitle=国产肝癌创新药多纳非尼一线治疗晚期肝细胞癌III期临床研究获得成功, objectType=article, longId=185534, objectId=9c1618553426, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9c1618553426, replyNumber=0, likeNumber=75, createdTime=2020-03-28, rootId=0, userName=tastas, userId=47c5349, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9c1618553426, moduleTitle=国产肝癌创新药多纳非尼一线治疗晚期肝细胞癌III期临床研究获得成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9c1618553426)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2050166, encodeId=f8162050166fc, content=<a href='/topic/show?id=581595e015' target=_blank style='color:#2F92EE;'>#III期临床研究#</a>, objectTitle=辉瑞宣布其JAK1抑制剂abrocitinib治疗特应性皮炎的第二项III期临床研究成功, objectType=article, longId=180178, objectId=8f301801e8b0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8f301801e8b0, replyNumber=0, likeNumber=77, createdTime=2020-05-03, rootId=0, userName=tastas, userId=47c5349, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8f301801e8b0, moduleTitle=辉瑞宣布其JAK1抑制剂abrocitinib治疗特应性皮炎的第二项III期临床研究成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8f301801e8b0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2050158, encodeId=1479205015847, content=<a href='/topic/show?id=581595e015' target=_blank style='color:#2F92EE;'>#III期临床研究#</a>, objectTitle=ALK阳性肺癌全新III期临床研究成果, objectType=article, longId=154858, objectId=84b91548588d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=84b91548588d, replyNumber=0, likeNumber=0, createdTime=2019-07-30, rootId=0, userName=tastas, userId=47c5349, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=84b91548588d, moduleTitle=ALK阳性肺癌全新III期临床研究成果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=84b91548588d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2050161, encodeId=0b5520501615e, content=<a href='/topic/show?id=581595e015' target=_blank style='color:#2F92EE;'>#III期临床研究#</a>, objectTitle=诺华的呼吸道合胞病毒疫苗ResVax在III期临床研究中失败, objectType=article, longId=161507, objectId=c9f516150e26, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c9f516150e26, replyNumber=0, likeNumber=68, createdTime=2019-04-17, rootId=0, userName=tastas, userId=47c5349, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c9f516150e26, moduleTitle=诺华的呼吸道合胞病毒疫苗ResVax在III期临床研究中失败, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c9f516150e26)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2050160, encodeId=62e42050160e1, content=<a href='/topic/show?id=581595e015' target=_blank style='color:#2F92EE;'>#III期临床研究#</a>, objectTitle=J Thorac Oncol：放疗分割方式是否与脑转移相关？III期临床研究CONVERT给你答案, objectType=article, longId=160563, objectId=3f571605635b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3f571605635b, replyNumber=0, likeNumber=76, createdTime=2019-08-25, rootId=0, userName=tastas, userId=47c5349, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3f571605635b, moduleTitle=J Thorac Oncol：放疗分割方式是否与脑转移相关？III期临床研究CONVERT给你答案, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3f571605635b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2050159, encodeId=5d8120501594f, content=<a href='/topic/show?id=581595e015' target=_blank style='color:#2F92EE;'>#III期临床研究#</a>, objectTitle=信达生物宣布达伯舒®一线胃癌III期临床研究完成首例患者给药, objectType=article, longId=158309, objectId=2e6815830948, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2e6815830948, replyNumber=0, likeNumber=72, createdTime=2019-10-17, rootId=0, userName=tastas, userId=47c5349, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2e6815830948, moduleTitle=信达生物宣布达伯舒®一线胃癌III期临床研究完成首例患者给药, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2e6815830948)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2050157, encodeId=9aae205015ef3, content=<a href='/topic/show?id=581595e015' target=_blank style='color:#2F92EE;'>#III期临床研究#</a>, objectTitle=Actelion门脉高压症新药Opsumit在III期临床研究中显示出良好前景, objectType=article, longId=149146, objectId=06fb149146c6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=06fb149146c6, replyNumber=0, likeNumber=82, createdTime=2019-08-10, rootId=0, userName=tastas, userId=47c5349, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=06fb149146c6, moduleTitle=Actelion门脉高压症新药Opsumit在III期临床研究中显示出良好前景, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=06fb149146c6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2050154, encodeId=cc822050154dd, content=<a href='/topic/show?id=581595e015' target=_blank style='color:#2F92EE;'>#III期临床研究#</a>, objectTitle=Lancet：度鲁特韦联合利匹韦林治疗HIV-1型III期临床研究, objectType=article, longId=125930, objectId=85ca1259307a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=85ca1259307a, replyNumber=0, likeNumber=58, createdTime=2018-03-26, rootId=0, userName=tastas, userId=47c5349, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=85ca1259307a, moduleTitle=Lancet：度鲁特韦联合利匹韦林治疗HIV-1型III期临床研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=85ca1259307a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2050156, encodeId=fae22050156cf, content=<a href='/topic/show?id=581595e015' target=_blank style='color:#2F92EE;'>#III期临床研究#</a>, objectTitle=安进公司宣布生物仿制药ABP 710的III期临床研究结果, objectType=article, longId=141928, objectId=2c18141928fb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2c18141928fb, replyNumber=0, likeNumber=73, createdTime=2018-08-03, rootId=0, userName=tastas, userId=47c5349, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2c18141928fb, moduleTitle=安进公司宣布生物仿制药ABP 710的III期临床研究结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2c18141928fb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2050155, encodeId=665c20501553c, content=<a href='/topic/show?id=581595e015' target=_blank style='color:#2F92EE;'>#III期临床研究#</a>, objectTitle=EUR J Cancer：一项比较SB3（曲妥珠单抗生物类似物）和曲妥珠单抗的III期临床研究, objectType=article, longId=130729, objectId=edaa130e2993, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=edaa130e2993, replyNumber=0, likeNumber=58, createdTime=2018-04-06, rootId=0, userName=tastas, userId=47c5349, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=edaa130e2993, moduleTitle=EUR J Cancer：一项比较SB3（曲妥珠单抗生物类似物）和曲妥珠单抗的III期临床研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=edaa130e2993)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2050153, encodeId=860b20501537b, content=<a href='/topic/show?id=581595e015' target=_blank style='color:#2F92EE;'>#III期临床研究#</a>, objectTitle=Lancet Neurol：依库珠单抗治疗抗乙酰胆碱受体抗体阳性难治性全身性重症肌无力III期临床研究, objectType=article, longId=117236, objectId=41dc11e236e9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=41dc11e236e9, replyNumber=0, likeNumber=67, createdTime=2018-03-30, rootId=0, userName=tastas, userId=47c5349, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=41dc11e236e9, moduleTitle=Lancet Neurol：依库珠单抗治疗抗乙酰胆碱受体抗体阳性难治性全身性重症肌无力III期临床研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=41dc11e236e9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2050149, encodeId=3a15205014938, content=<a href='/topic/show?id=581595e015' target=_blank style='color:#2F92EE;'>#III期临床研究#</a>, objectTitle=诺华III期临床研究显示ACZ885可降低心脏病发作幸存者心血管风险, objectType=article, longId=107035, objectId=461b10e035bf, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=461b10e035bf, replyNumber=0, likeNumber=51, createdTime=2017-10-14, rootId=0, userName=tastas, userId=47c5349, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=461b10e035bf, moduleTitle=诺华III期临床研究显示ACZ885可降低心脏病发作幸存者心血管风险, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=461b10e035bf)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2050152, encodeId=038e20501522d, content=<a href='/topic/show?id=581595e015' target=_blank style='color:#2F92EE;'>#III期临床研究#</a>, objectTitle=NEJM：埃博拉疫苗III期临床研究, objectType=article, longId=115953, objectId=514d11595351, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=514d11595351, replyNumber=0, likeNumber=79, createdTime=2018-06-16, rootId=0, userName=tastas, userId=47c5349, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=514d11595351, moduleTitle=NEJM：埃博拉疫苗III期临床研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=514d11595351)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

III期临床研究

2020-05-29

tastas (审核中...)

前往app查看评论内容

#III期临床研究#

维昇药业宣布其TransCon人生长激素将在国内开展III期临床研究

2020-07-27

tastas (审核中...)

前往app查看评论内容

#III期临床研究#

Strekin AG获得282万瑞士法郎的A轮融资，以完成STR001治疗突发感觉神经性听力损失的III期临床研究

2020-05-02

tastas (审核中...)

前往app查看评论内容

#III期临床研究#

J Gastroenterology：维多珠单抗对日本克罗恩病患者的疗效影响——III期临床研究

2020-11-12

tastas (审核中...)

前往app查看评论内容

#III期临床研究#

秦叔逵教授：呋喹替尼三线治疗中国转移性结直肠癌的III期临床研究（FRESCO）中的肝转移亚组分析|CSCO2019

2019-12-17

tastas (审核中...)

前往app查看评论内容

#III期临床研究#

全球III期临床研究：roxadustat的心血管安全性得到证实

2020-01-21

tastas (审核中...)

前往app查看评论内容

#III期临床研究#

III期临床研究CheckMate -9LA达到主要研究终点，与单独化疗相比，欧狄沃®（纳武利尤单抗）与低剂量伊匹木单抗联合化疗用于肺癌一线治疗，患者总生存获益

2020-04-30

tastas (审核中...)

前往app查看评论内容

#III期临床研究#

罗沙司他全球III期临床研究证实其心血管安全性

2019-11-22

tastas (审核中...)

前往app查看评论内容

#III期临床研究#

国产肝癌创新药多纳非尼一线治疗晚期肝细胞癌III期临床研究获得成功

2020-03-28

tastas (审核中...)

前往app查看评论内容

#III期临床研究#

辉瑞宣布其JAK1抑制剂abrocitinib治疗特应性皮炎的第二项III期临床研究成功

2020-05-03

tastas (审核中...)

前往app查看评论内容

#III期临床研究#

ALK阳性肺癌全新III期临床研究成果

2019-07-30

tastas (审核中...)

前往app查看评论内容

#III期临床研究#

诺华的呼吸道合胞病毒疫苗ResVax在III期临床研究中失败

2019-04-17

tastas (审核中...)

前往app查看评论内容

#III期临床研究#

J Thorac Oncol：放疗分割方式是否与脑转移相关？III期临床研究CONVERT给你答案

2019-08-25

tastas (审核中...)

前往app查看评论内容

#III期临床研究#

信达生物宣布达伯舒®一线胃癌III期临床研究完成首例患者给药

2019-10-17

tastas (审核中...)

前往app查看评论内容

#III期临床研究#

Actelion门脉高压症新药Opsumit在III期临床研究中显示出良好前景

2019-08-10

tastas (审核中...)

前往app查看评论内容

#III期临床研究#

Lancet：度鲁特韦联合利匹韦林治疗HIV-1型III期临床研究

2018-03-26

tastas (审核中...)

前往app查看评论内容

#III期临床研究#

安进公司宣布生物仿制药ABP 710的III期临床研究结果

2018-08-03

tastas (审核中...)

前往app查看评论内容

#III期临床研究#

EUR J Cancer：一项比较SB3（曲妥珠单抗生物类似物）和曲妥珠单抗的III期临床研究

2018-04-06

tastas (审核中...)

前往app查看评论内容

#III期临床研究#

Lancet Neurol：依库珠单抗治疗抗乙酰胆碱受体抗体阳性难治性全身性重症肌无力III期临床研究

2018-03-30

tastas (审核中...)

前往app查看评论内容

#III期临床研究#

诺华III期临床研究显示ACZ885可降低心脏病发作幸存者心血管风险

2017-10-14

tastas (审核中...)

前往app查看评论内容

#III期临床研究#

NEJM：埃博拉疫苗III期临床研究

2018-06-16

科室
- - 订阅+
  - 更多科室
工具
服务